| 摘要 |
Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism. |
